Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A drug being developed to treat diabetes.

Etymologies

Sorry, no etymologies found.

Examples

  • Roche's experimental medicine, called aleglitazar, was shown to be as good as or better at lowering blood sugar and certain blood fats in patients with type 2 diabetes as the market leader Actos, made by Takeda Pharmaceutical Co. of Japan.

    Roche Diabetes Drug in Late-Stage Test

  • In the cardiovascular area, Roche highlighted two drug candidates, aleglitazar for which late-stage trials started in the first quarter of 2010 and dalcetrapib for which Roche is currently enrolling patients in a late-stage trial.

    Roche to Push Ahead on Cancer Treatments

  • The bank cited experimental drugs such as atherosclerosis treatment dalcetrapib, diabetes treatment aleglitazar and schizophrenia treatment RG1678.

    Drug-Trial Setbacks Raise Pressure at Roche

  • The bank cited experimental drugs such as atherosclerosis treatment dalcetrapib, diabetes treatment aleglitazar and schizophrenia treatment RG1678.

    Drug-Trial Setbacks Raise Pressure at Roche

  • "Roche's suboptimal development for taspoglutide raises questions about the integrity of the development programs for their other large phase III programs," the bank said, singling out diabetes drug aleglitazar and cholesterol treatment dalceptrapib, two drugs that could also reach blockbuster status if they are approved.

    Blockbuster Odds Dim for Roche

  • The bank cited experimental drugs such as atherosclerosis treatment dalcetrapib, diabetes treatment aleglitazar and schizophrenia treatment RG1678.

    Drug-Trial Setbacks Raise Pressure at Roche

  • Roche has several late stage drugs outside the oncology area, including diabetes medicine aleglitazar and cholesterol treatment dalcetrapib.

    Roche to Cut 4,800 Jobs

  • Henry RR, et al "Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study"

    MedPageToday.com - medical news plus CME for physicians

  • The trend of changes over time suggested the maximum effect of aleglitazar on hemoglobin A1c concentration had yet to be reached at 16 weeks, whereas the impact on fasting plasma glucose peaked after eight weeks.

    MedPageToday.com - medical news plus CME for physicians

  • Explain to interested patients that aleglitazar is not FDA approved for any indication.

    MedPageToday.com - medical news plus CME for physicians

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.